[{"id":"c36bb106-df7a-452b-8b1f-240d487bcc1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02929290","created_at":"2021-01-18T14:23:12.967Z","updated_at":"2024-07-02T16:36:24.500Z","phase":"Phase 1","brief_title":"Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC","source_id_and_acronym":"NCT02929290","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-9016"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-09-13"}]